Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» DLBCL
DLBCL
FDA adcomm votes 11-2 to expand Roche's Polivy label in DLBCL
Endpoints
Thu, 03/9/23 - 10:21 pm
Roche
FDA
Polivy
DLBCL
Karyopharm’s Xpovio Wins Second FDA Approval for DLBCL Treatment
BioSpace
Tue, 06/23/20 - 10:53 am
Karyopharm
FDA
DLBCL
Xpovio
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Tue, 12/10/19 - 10:06 am
Novartis
Kymriah
CAR-T
DLBCL
ALL
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL
First patient dosed in unique biomarker guided Ph III study of enzastaurin + R-CHOP in high-risk diffuse large B-cell lymphoma (DLBCL)
CP Wire
Wed, 04/4/18 - 09:53 am
biomarkers
enzastaurin
Denovo Therapeutics
DLBCL
R-CHOP
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
Sun, 12/10/17 - 11:10 am
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma